The safety and efficacy of CKD-497 in patients with acute upper respiratory tract infection and bronchitis symptoms: a multicenter, double-blind, double-dummy, randomized, controlled, phase II clinical trial.

BACKGROUND: Acute upper respiratory tract infection (AURI) together with acute bronchitis is the most common illness worldwide. Botanical medicines used as expectorants and antitussives have proven to be effective while also having excellent safety margins. We aimed at evaluating the efficacy and safety of a new botanical drug, CKD-497, in patients with AURI and acute bronchitis.
METHODS: In this phase 2 study, 225 patients were enrolled and randomly assigned to one of four treatment groups: placebo (n=55), Synatura® (n=49), CKD-497 200 mg (n=68), or CKD-497 300 mg (n=53). The study drugs were administered three times daily over the course of 7 days. Primary endpoint was the change in the bronchitis severity score (BSS) from baseline to day 7. Secondary endpoint was evaluated based on clinical response rates on days 4 and 7. A safety analysis was also performed.
RESULTS: Between baseline and day 7, the mean BSS scores decreased significantly in each group (P<0.001): -4.04±1.85, -4.31±1.47, -4.09±1.48, and -4.28±1.69. However, neither the CKD-497 nor Synatura® group showed any significant effect on the difference in BSS change (P=0.75). The rate of clinical response was higher in the CKD-497 300 mg group as compared to the placebo only on day 4 (36% vs. 18%; P<0.05) and those having more severe bronchitis (phlegm score ≥3) showed a significant reduction of total BSS in the Synatura® and CKD-497 groups (P=0.042). No significant adverse events were observed in either of the CKD-497 groups.
CONCLUSIONS: CKD-497 and even the positive control drug had no significant effect on BSS change in this phase 2 clinical trial. However, CKD-497 300 mg had a mild but significant clinical improvement in early bronchitis patients with more severe phlegm. Considering both efficacy and safety, a future study using 300 mg of CKD-497 with a shorter-term endpoint is warranted in patients with more severe bronchitis symptoms. 2021 Journal of Thoracic Disease. All rights reserved.

Introduction

Acute upper respiratory tract infection (AURI) and acute bronchitis (AB) are among the most common diseases reported in outpatient settings (1). On average, adults are diagnosed with AURI and AB, often called the common cold, two to five times in a year (2,3). These diseases are associated with 40% of instances of absenteeism at work and 10% of emergent visits, which cause a huge social and economic burden (4-6). AURI and AB are defined as irritation and swelling in the airway without any symptoms of pneumonia (1,7). Generally, AURI is used to refer to pharyngitis, laryngitis, tonsillitis, and rhinitis, and its symptoms include cough, sore throat, runny nose, nasal congestion, headache, sneezing, malaise, and myalgia (7,8). The most common etiology of AURI and AB is infection with viruses including rhinovirus, influenza virus, adenovirus, enterovirus, and respiratory syncytial virus (9,10). These viruses directly invade the upper airway, leading to the development of AURI and AB. One of the body’s defenses for preventing the entry of these pathogens into the airway is mucus (11).

In a healthy individual, mucus traps these foreign organisms and transports them to the pharynx by mucociliary clearance, thus preventing them entering the deep respiratory system (12-14). However, this mucous homeostasis can sometimes fail to prevent AURI and AB, resulting in thick mucus, impairment of mucociliary clearance and coughing (14-16). In terms of treatment, the primary requirement for AURI and AB is relief from an increase in mucus production, i.e., phlegm, and cough using expectorants and antitussives. With regard to evaluating the effectiveness of expectorants and antitussives, the bronchitis severity score (BSS) consisting of five components including cough, phlegm production, rales/rhonchi, chest pain during coughing, and dyspnea assessed by physicians is considered a valid measurement tool and the change of total BSS is considered to be important (17-19).

Recently, botanical medicines have been found to be effective and safe for the treatment of respiratory diseases of both adult and children in double-blind, placebo-controlled clinical trials (17-19). Their formulations are capsule, syrup or tablet. Synatura® (a botanical drug chiefly comprising ivy leaf extract) has been reported to be effective for cough and phlegm reduction (18,19); ivy leaf extract has been approved for these indications by the European Medicines Agency (EMA). CKD-497, a botanical expectorant, has been developed by CKD Pharm; its pharmacological efficacy has been proven in vitro and in vivo (20). Hence, in this phase II clinical trial, we aimed to determine the efficacy and safety profile of CKD-497.

Methods

Study design

The trial included subjects with cough and phlegm caused by AURI and AB. This was a randomized, double-blind, placebo- and active component-controlled, four-group parallel design trial conducted in 15 centers in Korea from June 8, 2018 (when the first patient was enrolled) to March 21, 2019 (when the last patient was enrolled). The trial was conducted according to the principles of the Declaration of Helsinki and Korean Good Clinical Practice guidelines, and written informed consent was obtained from all patients. The trial protocol was approved by the Korean Food and Drug Administration (approval no. 176AURI/AB17014) and by the institutional and review board (IRB) at each center. This study was registered in the Clinical Trials Registry in Korea (31630) and Clinicaltrial.gov (NCT03726853) before the enrollment was started.

Patient selection and procedures

Two hundred and thirty-one patients between the ages of 19 and 75 years were screened. Of these, 225 patients who provided written informed consent were enrolled. The following subjects were included: non-smokers (subjects who had stopped smoking for more than a year at the time of enrollment were also eligible for inclusion), and subjects having symptoms such as cough and phlegm along with AURI and AB within 72 h of the time of enrollment and a BSS of ≥5 along with a cough and phlegm score of ≥2. The following subjects were excluded from the trial: those who were considered to need antibiotics during the trial; those with pneumonia, asthma, chronic obstructive pulmonary disease, tuberculosis, bronchiectasis, tumors, severe diabetes, hypertension, or any other disease that could interfere with the trial outcome; and lactating or pregnant women.

The patients who met the inclusion criteria were randomized at a ratio of 1:1:1:1 at visit 1. As shown in , the patients were divided into the following four groups: placebo (n=55), active control (Synatura®, n=49), CKD-497 200 mg (n=68), and CKD-497 300 mg (n=53). In all the groups, the respective intervention was administered three times a day for 7 days. The patients’ BSS and improvement of symptoms at hospital visit 2 (day 4±1) and visit 3 (day 7±1) were assessed by physicians. Furthermore, at every visit, the patients were followed up to confirm drug compliance and record concomitant medications, vital signs, blood test results, adverse events, and adverse drug reactions. Additionally, drug and disease history of the patients was investigated, and urine human chorionic gonadotropin (HCG) test, chest X-ray, and electrocardiography (ECG) were conducted at the screening (visit 1) and only urine HCG test and chest X-ray were performed at the final visit (visit 3).

Figure 1

Study design and flowchart of study participants. (A) A phase 2, randomized, double-blind, multi-center, parallel-group trial to evaluate the efficacy and safety of CKD-497 in patients with cough and phlegm due to acute upper respiratory infection and acute bronchitis; (B) the patients were assigned to placebo, Synatura syrup, CKD-497 200 or 300 mg.

Assessment

To quantify the efficacy of CKD-497 on AURI and AB, BSS and assessment of patients’ improvement by investigators and patients themselves were used as variables in the evaluation. Regarding BSS, physicians rated the patients’ symptoms, including cough, phlegm production, rales/rhonchi, chest pain during coughing, and dyspnea, at every visit on a scale of 0 to 4 (0= none, 1= mild, 2= moderate, 3= severe, and 4= very severe). The primary endpoint was the change in the total mean BSS at visit 3 from baseline (mean BSS at visit 3–mean BSS at visit 1). The secondary endpoints were as follows. (I) The first was the change in the total mean BSS at visit 2 from baseline visit. (II) The second was the change in the mean BSS for cough or phlegm at visit 2 or 3 from baseline. (III) The third was the change from visit 1 to visit 2 or 3 in the component of BSS (cough or phlegm) that rating was equal to and greater than 3 at visit 1. (IV) The fourth was the change from visit 1 to visit 2 or 3 in the total mean BSS, whose rating of cough or phlegm was equal to and higher than 3 at visit 1. (V) The final one was the improvement reported by investigators or the patients’ themselves on a scale of 1 to 5 (1= complete recover, 2= markedly recover, 3= slightly recover, 4= same, 5= worse) at visits 2 and 3 compared to the status at visit 1. Patients who reported a score of 1 or 2 were considered to show improvement and those who reported a score of 3 and higher were considered to be “non-improvement” group. To assess adverse events and adverse drug reactions (safety analysis), the following data collected by the investigators were analyzed: vital signs, chest X-ray, ECG findings, blood test results, and concomitant use of drugs.

Statistical analysis

Statistical analyses were performed using SAS® software (version 9.4; SAS Institute Inc., Cary, NC, USA). All tests were two-tailed, and significance was set at P<0.05. The data set for evaluating the effect of CKD-497 was as per that in . The sample size of each group was calculated as 55 on average if the difference of the change in BSS from baseline to visit 3 between the CKD-497 and placebo groups was considered as 1.6, the standard deviation (SD) 2.3, significance level 5%, statistical power 90%, and drop-out rate 20% (21). In total, more than 220 enrollments (55×4 groups) were needed, and the actual number of subjects enrolled was 225. For the primary and secondary endpoints, each experimental group was compared with the control or placebo group by using the Kruskal-Wallis test and Bonferroni post-hoc test after determining the changes in BSS at visit 2 or 3 compared to the BSS at visit 1. Then the BSS data adjusted for sex, smoking history, age, visiting month or season, clinical institute, personal disease history, and BSS at visit 1 was analyzed in additional secondary endpoint. With regard to symptom improvement, the Chi-square test was conducted to compare the experimental groups with the placebo or positive control group. Regarding the safety assessment, symptom incidences were indicated in percentages, and the data was analyzed using Chi-square test.

Results

Effects of CKD-497 on the BSS

Baseline characteristics and medical history of study subjects were not statistically different among the four groups ( and Table S1). As shown in Table S2, all but two patients complied with the drug schedule. BSS scores at baseline were 5.82±1.20, 5.63±0.88, 5.68±0.98, and 5.72±0.91 in the placebo, Synatura®, CKD-497 200 mg, and CKD-497 300 mg groups, respectively (P>0.05). To evaluate the effect of CKD-497 200 and 300 mg on AURI and AB at visit 3, changes in the total BSS average between visit 3 and 1 (mean BSS at visit 3–mean BSS at visit 1) were analyzed. The changes in the mean BSS were –4.04±1.85, –4.31±1.47, –4.09±1.48, and –4.28±1.69 in the placebo, positive control, CKD-497 200 mg, and CKD-497 300 mg groups, respectively (), suggesting significant intragroup differences in all groups (BSS at visit 1 vs. BSS at visit 3 in each group, P<0.001). However, neither the CKD-497 nor positive control group showed significant effect on the primary endpoint compared to the placebo group (P=0.75). In the per-protocol set, the non-compliance patients were excluded, and the results were the same.

Table 1

Baseline characteristics of study subjects

Variables	Total (n=225)			Placebo (n=55)			Synatura (n=49)			CKD-497 200 mg (n=68)			CKD-497 300 mg (n=53)		P value
	N	%		N	%		N	%		N	%		N	%
Gender															0.33b
Male	51	22.67		11	20.00		13	26.53		19	27.94		8	15.09
Female	174	77.33		44	80.00		36	73.47		49	72.06		45	84.91
Age, mean ± SD	39.69±11.96			39.27±9.81			37.90±11.72			40.87±13.09			40.26±12.80		0.62a
Smoke history															0.95b
Non-smoker	210	93.33		51	92.73		45	91.84		64	94.12		50	94.34
Smoker in the past	15	6.67		4	7.27		4	8.16		4	5.88		3	5.66
BMI, mean ± SD	22.95±3.21			22.62±2.82			22.92±3.06			23.29±3.28			22.87±3.66		0.76a
Body temperature, mean ± SD	36.66±0.34			36.73±0.35			36.64±0.38			36.64±0.34			36.63±0.31		0.27a
WBC, mean ± SD	6.08±1.61			6.30±1.76			6.49±2.00			5.93±1.36			5.67±1.25		0.07a
Neutrophil, mean ± SD	53.17±14.01			54.02±15.21			54.20±14.31			51.68±15.19			53.24±10.71		0.40a
Eosinophil, mean ± SD	2.39±2.13			2.11±1.35			1.92±1.62			2.41±1.83			3.09±3.18		0.06a

a, Kruskal-Wallis test; b, Chi-square test. SD, standard deviation; BMI, body mass index; WBC, white blood cell.

Table 2

Primary efficacy analysis of the change in total BSS according to groups

Variables (BSS total)	Placebo (n=55)	Synatura (n=49)	CKD-497 200 mg (n=68)	CKD-497 300 mg (n=53)
Baseline (visit 1), mean (SD)	5.82 (1.20)	5.63 (0.88)	5.68 (0.98)	5.72 (0.91)
Day 4 (visit 2), mean (SD)	3.56 (2.32)	2.88 (1.36)	3.10 (1.53)	2.85 (1.59)
Day 7 (visit 3), mean (SD)	1.78 (2.02)	1.33 (1.28)	1.59 (1.37)	1.43 (1.77)
Change (day 4–baseline)	–2.25 (1.75)	–2.76 (1.25)	–2.57 (1.51)	–2.87 (1.48)
P valuea	0.22
Change (day 7–baseline)	–4.04 (1.85)	–4.31 (1.47)	–4.09 (1.48)	–4.28 (1.69)
P valuea	0.75

a, Kruskal-Wallis test. BSS, bronchitis severity score; SD, standard deviation.

Effect of CKD-497 on the secondary endpoints

For the secondary endpoints, five different analyses were performed. In the first, the effect of CKD-497 200 and 300 mg at visit 2 was compared to that at visit 1, and the results were as follows: –2.25±1.75 (placebo group), –2.76±1.25 (positive control group), –2.57±1.51 (CKD-497 200 mg group), and –2.87±1.48 (CKD-497 300 mg group) (). The intergroup difference was not statistically significant (P=0.22). To determine whether CKD-497 200 or 300 mg affected the BSS for cough or phlegm at visits 2 or 3, we determined the differences between visit 2 or 3 and visit 1. As shown in Table S3, the results showed no clinically significant difference in statistics.

Analysis of covariance with an adjustment for the clinical institute and baseline BSS was also performed to compare the change in BSS from baseline to visit 2 or 3 between the four groups and showed no differences (Table S4). After adjustment, we identified the patients whose total BSS average was equal to and greater than 3 (tBSS3) at visit 1 and recorded the changes in tBSS3 at visit 2 or 3. Changes in the total average of tBSS3 at visit 2 or 3 compared to tBSS3 at visit 1 showed no effect of CKD-497 (data not shown). Furthermore, the patients whose average cough BSS or phlegm BSS was equal to and greater than 3 (cBSS3 or pBSS3) at visit 1 were identified, and the changes in the mean of total BSS at each visit was shown in (Tables S5,S6). Interestingly, although there was no difference of the change in the mean of total BSS from baseline among the four groups including only those with cBSS3 (), the changes at visit 2 showed a statistical difference (*, P=0.042 by Kruskal-Wallis test) in those with pBSS3 ().

Figure 2

The mean of total BSS in study groups of placebo, Synatura, CKD-497 200 or 300 mg at each visit. (A) The changes of the mean of total BSS from baseline showed no significant difference among the four groups including only those with cough score at visit 1 ≥3; (B) the changes of the mean of total BSS at visit 2 showed a statistical difference in the four groups including only those with phlegm score at visit 1 ≥3 (*, P=0.042 by Kruskal-Wallis test). Bars indicate standard error of means. BSS, bronchitis severity score.

The investigators and patients rated the improvement in symptoms at visit 2 and 3 compared to the status at visit 1 (). Evaluation of patients’ recovery at visit 2 from the corresponding status at visit 1 indicated that compared to the placebo treatment, the treatment with CKD-497 300 mg significantly improved symptoms. More importantly, both the investigators and patients confirmed significant improvements at visit 2 (P=0.0323, 0.0384).

Figure 3

Clinical response rate of symptom reported by investigators and patients. (A) Improvement of symptoms at visit 2 and 3 was asked to investigators and analyzed their responding; (B) improvement of symptoms at visit 2 and 3 was assessed by patients and analyzed their responding. *, Chi-square test between CKD-497 300 mg vs. placebo.

Safety assessment

In total, there were 27 adverse events in 21 patients (9.33%), and intergroup differences were not significant (P=0.84, ). There were 6 adverse events among 5 patients (9.43%) in the CKD-497 300 mg group and 10 events among 8 patients (11.76%) in the CKD-497 200 mg group. Similarly, there were 5 events of adverse effects among 4 patients (8.16%) in the positive control group and 6 events among 4 patients (7.27%) in the placebo group ().

Table 3

Adverse events and adverse drug reactions

Variables	Total (n=225)			Placebo (n=55)			Synatura (n=49)			CKD-497 200 mg (n=68)			CKD-497 300 mg (n=53)		P value
	Persons (%)	Events		Persons (%)	Events		Persons (%)	Events		Persons (%)	Events		Persons (%)	Events
Total adverse events	21 (9.33)	27		4 (7.27)	6		4 (8.16)	5		8 (11.76)	10		5 (9.43)	6	0.84
Adverse drug reactions	8 (3.56)	10		2 (3.64)	3		3 (6.12)	4		3 (4.41)	3		0	0	0.34
Severe adverse events	0	0		0	0		0	0		0	0		0	0	–
Severe adverse drug reactions	0	0		0	0		0	0		0	0		0	0	–

Overall, there were 10 cases of adverse drug reactions in 8 patients (3.56%), and intergroup differences were not significant (P=0.34). There were no cases of adverse drug reactions in the CKD-497 300 mg group, and 3 cases among 3 patients (4.41%) in the CKD-497 200 mg group. In the positive control and placebo groups, there were 4 and 3 cases of adverse drug effects in 3 (6.12%) and 2 (3.64%) patients, respectively. There was no severe adverse events or severe adverse drug reactions.

Discussion

The purpose of this phase II study was to test the safety and efficacy of CKD-497, a new botanical drug developed by CKD Pharm., which could facilitate the treatment of AURI and AB and prevent progression of severe respiratory symptoms. It is notable that CKD-497 consists of edible botanical sources (20). Furthermore, the safety assessment conducted in this study revealed no concerning adverse drug effect or severe adverse events. In this phase II clinical trial of CKD-497, primary and secondary endpoints were evaluated in various analyses using a valid measurement tool of BSS. With regard to the fact that the primary outcome did not reach a statistical significance in this trial, this finding was attributable to the milder symptoms, reflected by low BSS values at baseline in our study subjects than previous studies (17-19,21). We calculated the sample size based on the previous study (21) that enrolled patients with more severe BSS than our study, which could be the main reason that CKD-497 showed milder effect on this trial.

It is well-established and accepted that mild viral URIs resolve spontaneously without any medications. Not only in CKD-497 and active comparator group but also in placebo group, the total BSS showed significant improvements between baseline visit 1 and 2 or 3. However, it is notable that among those with more severe phlegm, there was a significant difference in BSS at visit 2 but not at visit 3 suggesting earlier recovery in CKD-497 300 mg group than placebo group, which was associated with clinical improvement in the group. Although the primary endpoint did not reach a statistical significance, the change in BSS was numerically larger in the experimental drug groups than in the placebo group; however, the difference was not significant, which could be due to a lack of efficacy of the drug CKD497. Moreover, we did not consider multiple comparisons of four groups when we calculated sample size as shown in submitted protocol (NCT03726853).

Three limitations of this trial should be noted. First, the lack of study power and the characteristics of the study subjects who had milder symptoms at baseline resulted in no effect on the primary endpoint. However, with regard to the secondary endpoints, it was important that both investigators and patients in the CKD-497 300 mg group reported significant improvement of symptoms at visit 2. In addition, total BSS decreased at visit 2 in subgroup analysis of the patients having more phlegm score. These findings suggest that CKD-479 could favorably treat specific symptoms of AURI or AB. Since the present study is a phase II study to determine dose of study drugs and investigate a little more safety aspect rather than efficacy, a further study of phase III trial focusing on the efficacy of 300 mg CKD-497 with a larger sample to test for any clinical efficacy of CKD-497 is needed in patients with more severe bronchitis symptoms.

Second, there was a lack of gender balance in our study on randomization. The ratio was 8:2 between female and male in the order. This imbalance was more affected by the small sample size. Again, further investigation with larger number of study subjects or stratified randomization according to gender would supplement our investigation.

Third, we analyzed our data using analysis of variance, which is a predefined statistical method, as opposed to using a generalized estimating equation (GEE) model, which can take the time effect into consideration. Although the missing data of outcome occurred only in two subjects and the results were the same when we reanalyzed our data using the GEE method, the sample size calculated by the two methods would be different on planning study design and might have affected our results. Further study with a more sophisticated calculation of sample size based on accurate statistical methods is needed.

In conclusion, this phase II clinical trial showed that there was no significant effect of CKD-497 and the positive control drug on BSS change. However, CKD-497 300 mg had a mild but significant clinical improvement in early bronchitis patients with more severe phlegm. Considering both efficacy and safety, a future study using 300 mg of CKD-497 with a shorter-term endpoint is warranted in patients with more severe bronchitis symptoms.

The article’s supplementary files as